Celltrion Inc
KRX:068270

Watchlist Manager
Celltrion Inc Logo
Celltrion Inc
KRX:068270
Watchlist
Price: 173 500 KRW -0.12% Market Closed
Market Cap: 36T KRW
Have any thoughts about
Celltrion Inc?
Write Note

Celltrion Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Celltrion Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Celltrion Inc
KRX:068270
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SK Bioscience Co Ltd
KRX:302440
Research & Development
-â‚©85.7B
CAGR 3-Years
-52%
CAGR 5-Years
-52%
CAGR 10-Years
N/A
Green Cross Corp
KRX:006280
Research & Development
-â‚©153.7B
CAGR 3-Years
-2%
CAGR 5-Years
-5%
CAGR 10-Years
-7%
H
Hugel Inc
KOSDAQ:145020
Research & Development
-â‚©8.4B
CAGR 3-Years
11%
CAGR 5-Years
4%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Research & Development
-â‚©17.7B
CAGR 3-Years
-38%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Research & Development
-â‚©28.6B
CAGR 3-Years
-23%
CAGR 5-Years
-34%
CAGR 10-Years
N/A
No Stocks Found

Celltrion Inc
Glance View

Market Cap
36T KRW
Industry
Biotechnology

Celltrion Inc. is a South Korean biopharmaceutical company that has made significant strides in the development and commercialization of biosimilars, monoclonal antibodies, and novel therapeutics. Established in 2002, the company has positioned itself as a key player in the global pharmaceutical landscape, particularly known for its commitment to making biological drugs more accessible and affordable. With a robust pipeline of products targeting conditions such as autoimmune diseases, cancer, and infectious diseases, Celltrion leverages state-of-the-art biotechnology and a strong emphasis on research and development. This focus not only enhances its product offerings but also champions the company’s mission of improving patient outcomes worldwide. As the global market for biosimilars continues to expand, driven by increasing healthcare costs and an aging population, Celltrion stands at the forefront, equipped with a solid operational framework and a strategic partnership approach. The company’s flagship products, like Remsima, a biosimilar to Remicade, have achieved notable success, gaining approval in numerous countries and establishing a strong revenue stream. With its plans to diversify its product portfolio, including innovative therapies in oncology, Celltrion is poised for growth. For investors, this translates into a promising opportunity to tap into a company that not only prioritizes innovation but also operates within a rapidly evolving market characterized by increasing demand for more affordable biologics.

Intrinsic Value
187 892.7 KRW
Undervaluation 8%
Intrinsic Value
Price

See Also

Back to Top